The initial treatments administered made no difference. Worried, the family went to Blanche Gomes Hospital in Brazzaville, then to the Center for Major Endemic Diseases for further examinations. The diagnosis came back: tuberculosis. The shock was devastating."I cried all day.", she says. Beyond the illness, it is the fear of infecting her children and seeing her future collapse that overwhelms her.

Yet, behind this devastating diagnosis, a comprehensive care system was put in place. Clarisse began a six-month treatment. The side effects were difficult but gradual, and her condition improved. She gained weight, regained her strength, and above all, found hope. In a country like the Republic of Congo, where tuberculosis remains one of the leading infectious threats, her story illustrates both the vulnerability of patients and the progress of the healthcare system. In 2024, approximately 19,000 people were affected by the disease.

But the combined efforts of the Ministry of Health, UNDP, the Global Fund, and their partners have reduced cases by 13% and mortality by about a third since 2015. On the ground, this progress also relies on discreet but essential actors. In Brazzaville, Mary Vincent Paola Passy Mambou ensures the secure transport of biological samples. She travels sometimes difficult distances, guaranteeing that the samples arrive at the laboratories on time.

This often invisible logistical link reduces the geographical and financial barriers that still prevent many patients from accessing diagnosis. For despite free testing and treatment, indirect costs—transportation, lost income, and distance from healthcare facilities—continue to be significant. Nearly one in three families still faces financial hardship related to the illness.

The technological advances, however, are very real. The National Reference Laboratory for Mycobacteria in Brazzaville, upgraded to biosafety level 3 according to WHO standards, now allows for faster and safer diagnoses. The introduction of rapid molecular tests such as Xpert MTB/RIF in 31 healthcare facilities has significantly improved detection, particularly of resistant strains. "Results are available in about 24 hours. Patients appreciate this speed," explains Dr. Darrel Ornelle Elion Assiana, head of the laboratory.

This acceleration changes everything: earlier treatment, safer medical decisions, and better monitoring of resistant cases. Between 2022 and 2024, the use of WHO-recommended tests increased by 133%, and bacteriological confirmation of cases more than doubled.

For Clarisse, this system made all the difference. After several months of treatment, she finally received confirmation of her recovery. A personal, intimate, almost silent victory. "I was cured," she says simply, as if breathing again.

Its story is part of a larger movement: that of a country trying to push back one of the world's deadliest infectious diseases, which was still responsible for more than a million deaths in 2024. But it also highlights a more fragile reality: without sustainable funding and sustained efforts, progress can easily be reversed.

However, behind this serious diagnosis, a care plan is put in place. Clarisse begins a six-month treatment.

At the end of the journey, one thing becomes clear. Fighting tuberculosis is not just about treating a disease. It's about rebuilding lives, providing security for families, and strengthening a healthcare system capable of sustaining the long term. And in this fight, every recovery, like Clarisse's, becomes more than a medical outcome: it's a sign that life can go on, despite everything.